Table 4. Number of pathologic nodal residual tumors according to breast pCR and subtype (%).

Characteristics	Breast pCR				Total	No breast pCR				Total
	0	1	2	≥3		0	1	2	≥3
N0
HR+HER2−	15 [75]	2 [10]	0 [0]	3 [15]	20	74 [45]	23 [14]	17[10]	49 [30]	163
HR+HER2+	20 [91]	2 [9]	0 [0]	0 [0]	22	33 [66]	5 [10]	1 [2]	11 [22]	50
HR−HER2+	20 [91]	1 [5]	1 [5]	0 [0]	22	35 [73]	4 [8]	2 [4]	7 [15]	48
TNBC	21 [100]	0 [0]	0 [0]	0 [0]	21	36 [65]	6 [11]	8 [15]	5 [9]	55
Total	76 [89]	5 [6]	1 [1]	3 [4]	85	178 [56]	38 [12]	28 [9]	72 [23]	316
N1
HR+HER2−	36 [68]	3 [6]	6 [11]	8 [15]	53	71 [26]	60 [22]	32 [12]	107 [40]	270
HR+HER2+	36 [75]	5 [10]	4 [8]	3 [6]	48	51 [38]	28 [21]	14 [10]	43 [31]	136
HR−HER2+	31 [74]	7 [17]	1 [2]	3 [7]	42	39 [54]	10 [14]	5 [7]	18 [25]	72
TNBC	31 [76]	4 [10]	1 [2]	5 [12]	41	32 [44]	16 [22]	6 [8]	19 [26]	73
Total	134 [73]	19 [10]	12 [7]	19 [10]	184	193 [35]	114 [21]	57 [10]	187 [34]	551

pCR, pathologic complete response; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; +, positive; −, negative.